Attenuated response to purified protein derivative in patients with rheumatoid arthritis [11]

Annals of the Rheumatic Diseases

Volumn 65, Issue 7, 2006, Pages 980-

  Nizam, S ^a   Emery, P ^a  

^a CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; PROTEIN DERIVATIVE;

CELLULAR IMMUNITY; CLINICAL PRACTICE; HEPATITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MEDICAL LITERATURE; MEDICAL SOCIETY; PRIORITY JOURNAL; PROPHYLAXIS; RHEUMATOID ARTHRITIS; RISK FACTOR; TUBERCULOSIS;

ARTHRITIS, RHEUMATOID; HUMANS; IMMUNITY, CELLULAR; PREDICTIVE VALUE OF TESTS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 33745686176     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.050161     Document Type: Letter

References (3)

1. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1.
2. Emery P, Panayi GS, Nouri AME. Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis. Clin Exp Immunol 1984;57:123-9.
3. BTS. British Thoracic Society Standards of Care Committee. British Thoracic Society recommendations for assessing risk and for managing mycobacterium tuberculosis infection and disease in patients due to start anti-TNF Rx. Thorax 2005;60:800-5.